Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Executive Summary

Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster sales. J&J adds that it’s planning 40 line extensions, with 10 that could yield $500m annually each.

You may also be interested in...



Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership

Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.

J&J Plots Five-Year Pharma Growth Plan Around Mega-Brands And Launches

Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.

AbbVie/J&J's Imbruvica On Track For New Indication In Graft-Versus-Host Disease

Results suggest 67% objective response rate in second-line+ chronic graft versus host disease; Phase III study is already testing Imbruvica for new onset disease.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC097507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel